Research
Hormonal
High levels of 12α-hydroxylated bile acids (derived from the classical pathway) are associated with metabolic disorders like insulin resistance and type 2 diabetes, whereas a higher ratio of non-12α-hydroxylated bile acids is beneficial.
Monitor bile acid profiles if possible; a lower ratio of 12α-hydroxylated bile acids (like cholic acid) to non-12α-hydroxylated bile acids (like chenodeoxycholic acid) may be a marker of better metabolic health.
ModerateRefutesMEDIUM confidence
increased CYP8B1-derived 12-OH BAs were associated with metabolic disorders such as insulin resistance and T2DM in humans
Why this rating
Based on human observational studies and mouse models cited in the review.
Source
Targeting the alternative bile acid synthetic pathway for metabolic diseases
Wei Jia et al. · Protein & Cell · 2020
DOI 10.1007/s13238-020-00804-9
narrative_reviewCited 318×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Activation of the alternative bile acid synthetic pathway, specifically via increased CYP7B1 expression and non-12α-hydroxylated bile acids (e.g., CDCA, TUDCA), improves glucose and lipid metabolism by reducing lipid absorption and enhancing energy expenditure.Moderate
- Inhibition of intestinal bile salt hydrolase (BSH) activity by compounds like theabrownin or riboflavin increases conjugated bile acids in the distal ileum, which inhibits intestinal FXR signaling and upregulates hepatic CYP7B1, thereby promoting the alternative bile acid pathway.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →